Adaptation and learning of molecular networks as a description of cancer development at the systems-level: Potential use in anti-cancer therapies

Seminars in Cancer Biology

Volumn 23, Issue 4, 2013, Pages 262-269

  Gyurkó, Dávid M ^a   Veres, Dániel V ^a   Módos, Dezsó ^a,b   Lenti, Katalin ^a   Korcsmáros, Tamás ^b   Csermely, Peter ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

Adaptation; Anti cancer therapies; Cancer attractors; Cancer development; Epithelial mesenchymal transition; Interactome; Networks; Signaling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN;

CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL HETEROGENEITY; CELL TRANSFORMATION; CHROMATIN STRUCTURE; CONFORMATIONAL TRANSITION; CONTROL STRATEGY; DEFORMITY; ENTROPY; GENE MUTATION; GENE REGULATORY NETWORK; HUMAN; INTRACELLULAR SIGNALING; LEARNING ALGORITHM; MALIGNANT TRANSFORMATION; METABOLISM; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; PHENOTYPIC PLASTICITY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL NOISE RATIO; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 84881218284     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.06.005     Document Type: Review

References (98)

1. Kitano H. Cancer as a robust system: implications for anticancer therapy. Nature Reviews Cancer 2004, 4:227-235.
2. Kitano H. Biological robustness. Nature Reviews Genetics 2004, 5:826-837.
3. Huang S., Ernberg I., Kauffman S. Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Seminars in Cell & Developmental Biology 2009, 20:869-876.
4. Pujadas E., Feinberg A.P. Regulated noise in the epigenetic landscape of development and disease. Cell 2012, 148:1123-1131.
5. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
6. Marusyk A., Almendro V., Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?. Nature Reviews Cancer 2012, 12:323-334.
7. Teschendorff A.E., Severini S. Increased entropy of signal transduction in the cancer metastasis phenotype. BMC Systems Biology 2010, 4:104-116.
8. West J., Bianconi G., Severini S., Teschendorff A.E. Differential network entropy reveals cancer system hallmarks. Scientific Reports 2012, 2:802-809.
9. Breitkreutz D., Hlatky L., Rietman E., Tuszynski J.A. Molecular signaling network complexity is correlated with cancer patient survivability. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:9209-9212.
10. Axelrod R., Axelrod D.E., Pienta K.J. Evolution of cooperation among tumor cells. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:13474-13479.
11. Bonavia R., Inda M.M., Cavenee W.K., Furnari F.B. Heterogeneity maintenance in glioblastoma: a social network. Cancer Research 2011, 71:4055-4060.
12. Creixell P., Schoof E.M., Erler J.T., Linding R. Navigating cancer network attractors for tumor-specific therapy. Nature Biotechnology 2012, 30:842-848.
13. Wu Y., Garmire L.X., Fan R. Inter-cellular signaling network reveals a mechanistic transition in tumor microenvironment. Integrative Biology 2012, 4:1478-1486.
14. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nature Reviews Cancer 2002, 2:442-454.
15. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation 2009, 119:1420-1428.
16. Tang D.G. Understanding cancer stem cell heterogeneity and plasticity. Cell Research 2012, 22:457-472.
17. Gáspár M.E., Csermely P. Rigidity and flexibility of biological networks. Briefings in Functional Genomics 2012, 11:443-456.
18. Guck J., Schinkinger S., Lincoln B., Wottawah F., Ebert S., Romeyke M., et al. Optical deformability as an inherent cell marker for testing malignant transformation and metastatic competence. Biophysical Journal 2005, 88:3689-3698.
19. Zhang W., Kai K., Choi D.S., Iwamoto T., Nguyen Y.H., Wong H., et al. Microfluidics separation reveals the stem-cell-like deformability of tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:18707-18712.
20. Kauffman S. Differentiation of malignant to benign cells. Journal of Theoretical Biology 1971, 31:429-451.
21. Rajapakse I., Perlman M.D., Scalzo D., Kooperberg C., Groudine M., Kosak S.T. The emergence of lineage-specific chromosomal topologies from coordinate gene regulation. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:6679-6684.
22. Buganim Y., Faddah D.A., Cheng A.W., Itskovich E., Markoulaki S., Ganz K., et al. Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell 2012, 150:1209-1222.
23. Lovén J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
24. Whyte W.A., Orlando D.A., Hnisz D., Abraham B.J., Lin C.Y., Kagey M.H., et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 2013, 153:307-319.
25. Rajapakse I., Groudine M., Mesbahi M. Dynamics and control of state-dependent networks for probing genomic organization. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:17257-17262.
26. Csermely P., Korcsmaros T., Kiss H.J.M., London G., Nussinov R. Structure and dynamics of molecular networks: a novel paradigm of drug discovery. A comprehensive review. Pharmacology & Therapeutics 2013, 138:333-408.
27. Dulbecco R. Cancer progression: the ultimate challenge. International Journal of Cancer. Supplement 1989, 4:6-9.
28. Hornberg J.J., Bruggeman F.J., Westerhoff H.V., Lankelma J. Cancer: a systems biology disease. BioSystems 2006, 83:81-90.
29. Dorogovtsev S., Mendes J. Evolution of networks. Advances in Physics 2002, 51:1079-1187.
30. Holme P., Saramäki J. Temporal networks. Physics Reports 2012, 519:97-125.
31. Pál C., Papp B., Lercher M.J. An integrated view of protein evolution. Nature Reviews Genetics 2006, 7:337-348.
32. Pazos F., Valencia A. Protein co-evolution, co-adaptation and interactions. EMBO Journal 2008, 27:2648-2655.
33. Gelman H., Platkov M., Gruebele M. Rapid perturbation of free-energy landscapes: from in vitro to in vivo. Chemistry 2012, 18:6420-6427.
34. Delsanto P.P., Romano A., Scalerandi M., Pescarmona G.P. Analysis of a "phase transition" from tumor growth to latency. Physical Review E 2000, 62:2547-2554.
35. Barabasi A.L., Albert R. Emergence of scaling in random networks. Science 1999, 286:509-512.
36. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
37. Wade M., Li Y.C., Wahl G.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nature Reviews Cancer 2012, 13:83-96.
38. Schwartz J.M., Tian K., Rajendran R., Doddananjaiah M., Krstic-Demonacos M. Dynamics of DNA damage induced by pathways of cancer. PLoS ONE 2013, 8. in press.
39. Fraser H.B. Modularity and evolutionary constraint on proteins. Nature Genetics 2005, 37:351-352.
40. Milo R., Shen-Orr S., Itzkovitz S., Kashtan N., Chklovskii D., Alon U. Network motifs: simple building blocks of complex networks. Science 2002, 298:824-827.
41. Ma W., Trusina A., El-Samad H., Lim W., Tang C. Defining network topologies that can achieve biochemical adaptation. Cell 2009, 138:760-773.
42. Spirin V., Mirny L. Protein complexes and functional modules in molecular networks. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:12123-12128.
43. Taylor I.W., Linding R., Warde-Farley D., Liu Y., Pesquita C., Faria D., et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nature Biotechnology 2009, 27:199-204.
44. Horvath S., Zhang B., Carlson M., Lu K.V., Zhu S., Felciano R.M., et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:17402-17407.
45. Furlong L.I. Human diseases through the lens of network biology. Trends in Genetics 2012, 29:150-159.
46. Mihalik á., Csermely P. Heat shock partially dissociates the overlapping modules of the yeast protein-protein interaction network: a systems level model of adaptation. PLoS Computational Biology 2011, 7:e1002187.
47. Gyurkó M.D., Soti C., Stetak A., Csermely P. System level mechanisms of adaptation, learning, memory formation and evolvability: the role of chaperone and other networks. Current Protein & Peptide Science 2013, 14. in press.
48. Jonsson P.F., Bates P.A. Global topological features of cancer proteins in the human interactome. Bioinformatics 2006, 22:2291-2297.
49. Yu H., Kim P.M., Sprecher E., Trifonov V., Gerstein M. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Computational Biology 2007, 3:e59.
50. Csermely P. Creative elements: network-based predictions of active centres in proteins and cellular and social networks. Trends in Biochemical Sciences 2008, 33:569-576.
51. Iakoucheva L.M., Brown C.J., Lawson J.D., Obradović Z., Dunker A.K. Intrinsic disorder in cell-signaling and cancer-associated proteins. Journal of Molecular Biology 2002, 323:573-584.
52. Uversky V.N., Oldfield C.J., Midic U., Xie H., Xue B., Vucetic S., et al. Unfoldomics of human diseases: linking protein intrinsic disorder with diseases. BMC Genomics 2009, 10:S7.
53. Mahmoudabadi G., Rajagopalan K., Getzenberg R.H., Hannenhalli S., Rangarajan G., Kulkarni P. Intrinsically disordered proteins and conformational noise: implications in cancer. Cell Cycle 2013, 12:26-31.
54. Kar G., Gursoy A., Keskin O. Human cancer protein-protein interaction network: a structural perspective. PLoS Computational Biology 2009, 5:e1000601.
55. Coulombe B. Mapping the disease protein interactome: toward a molecular medicine GPS to accelerate drug and biomarker discovery. Journal of Proteome Research 2011, 10:120-125.
56. Sardiu M.E., Washburn M.P. Building protein-protein interaction networks with proteomics and informatics tools. Journal of Biological Chemistry 2011, 286:23645-23651.
57. Wachi S., Yoneda K., Wu R. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 2005, 21:4205-4208.
58. Hase T., Tanaka H., Suzuki Y., Nakagawa S., Kitano H. Structure of protein interaction networks and their implications on drug design. PLoS Computational Biology 2009, 5:e1000550.
59. Xia J., Sun J., Jia P., Zhao Z. Do cancer proteins really interact strongly in the human proteinprotein interaction network?. Computational Biology and Chemistry 2011, 35:121-125.
60. Lin C.-C., Chen Y.-J., Chen C.-Y., Oyang Y.-J., Juan H.-F., Huang H.-C. Crosstalk between transcription factors and microRNAs in human protein interaction network. BMC Systems Biology 2012, 6:18-30.
61. Klinke D.J. Signal transduction networks in cancer: quantitative parameters influence network topology. Cancer Research 2010, 70:1773-1782.
62. Korcsmáros T., Farkas I.J., Szalay M.S., Rovó P., Fazekas D., Spiró Z., et al. Uniformly curated signaling pathways reveal tissue-specific cross-talks, novel pathway components, and drug target candidates. Bioinformatics 2010, 26:2042-2050.
63. Mendoza M.C., Er E.E., Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends in Biochemical Sciences 2011, 36:320-328.
64. Lewitzky M., Simister P.C., Feller S.M. Beyond "furballs" and "dumpling soups" - towards a molecular architecture of signaling complexes and networks. FEBS Letters 2012, 586:2740-2750.
65. Nussinov R., Ma B., Tsai C.-J. A broad view of scaffolding suggests that scaffolding proteins can actively control regulation and signaling of multienzyme complexes through allostery. Biochimica et Biophysica Acta 2013, 1834:820-829.
66. Muscolini M., Montagni E., Palermo V., Di Agostino S., Gu W., Abdelmoula-Souissi S., et al. The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein. Journal of Biological Chemistry 2011, 286:39693-39702.
67. Pálfy M., Reményi A., Korcsmáros T. Endosomal crosstalk: meeting points for signaling pathways. Trends in Cell Biology 2012, 22:447-456.
68. Fudenberg G., Getz G., Meyerson M., Mirny L.A. High order chromatin architecture shapes the landscape of chromosomal alterations in cancer. Nature Biotechnology 2011, 29:1109-1113.
69. Rickman D.S., Soong T.D., Moss B., Mosquera J.M., Dlabal J., Terry S., et al. Oncogene-mediated alterations in chromatin conformation. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:9083-9088.
70. Sandhu K.S., Li G., Poh H.M., Quek Y.L., Sia Y.Y., Peh S.Q., et al. Large-scale functional organization of long-range chromatin interaction networks. Cell Reports 2012, 2:1207-1219.
71. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nature Reviews Cancer 2006, 6:857-866.
72. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
73. Mattiske S., Suetani R.J., Neilsen P.M., Callen D.F. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiology, Biomarkers & Prevention 2012, 21:1236-1243.
74. Volinia S., Galasso M., Costinean S., Tagliavini L., Gamberoni G., Drusco A., et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Research 2010, 20:589-599.
75. Ma H., Goryanin I. Human metabolic network reconstruction and its impact on drug discovery and development. Drug Discovery Today 2008, 13:402-408.
76. Shlomi T., Benyamini T., Gottlieb E., Sharan R., Ruppin E. Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect. PLoS Computational Biology 2011, 7:e1002018.
77. Yang W., Zheng Y., Xia Y., Ji H., Chen X., Guo F., et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nature Cell Biology 2012, 14:1295-1304.
78. Katoh M., Katoh M. Bioinformatics for cancer management in the post-genome era. Technology in Cancer Research and Treatment 2006, 2:73-182.
79. Nussinov R., Tsai C.J., Csermely P. Allo-network drugs: harnessing allostery in cellular networks. Trends in Pharmacological Sciences 2011, 32:686-693.
80. Csermely P., Agoston V., Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends in Pharmacological Sciences 2005, 26:178-182.
81. Awan A., Bari H., Yan F., Moksong S., Yang S., Chowdhury S., et al. Regulatory network motifs and hotspots of cancer genes in a mammalian cellular signalling network. IET Systems Biology 2007, 1:292-297.
82. Budd W.T., Weaver D.E., Anderson J., Zehner Z.E. microRNA dysregulation in prostate cancer: network analysis reveals preferential regulation of highly connected nodes. Chemistry & Biodiversity 2012, 9:857-867.
83. Freudlsperger C., Bian Y., Contag Wise S., Burnett J., Coupar J., Yang X., et al. TGF-? and NF-?B signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers. Oncogene 2013, 32:1549-1559.
84. Rosado J.O., Henriques J.P., Bonatto D. A systems pharmacology analysis of major chemotherapy combination regimens used in gastric cancer treatment: predicting potential new protein targets and drugs. Current Cancer Drug Targets 2011, 11:849-869.
85. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature Reviews Molecular Cell Biology 2011, 12:21-35.
86. Ruffner H., Bauer A., Bouwmeester T. Human protein-protein interaction networks and the value for drug discovery. Drug Discovery Today 2007, 12:709-716.
87. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. Journal of Clinical Investigation 2008, 118:3065-3074.
88. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
89. Murthy D., Attri K.S., Gokhale R.S. Network, nodes and nexus: systems approach to multitarget therapeutics. Current Opinion in Biotechnology 2013, in press. 10.1016/j.copbio.2013.02.009.
90. Sakharkar M.K., Shashni B., Sharma K., Dhillon S.K., Ranjekar P.R., Sakharkar K.R. Therapeutic implications of targeting energy metabolism in breast cancer. PPAR Research 2013, 2013:109285.
91. Nibbe R.K., Koyutürk M., Chance M.R. An integrative-omics approach to identify functional sub-networks in human colorectal cancer. PLoS Computational Biology 2010, 6:e1000639.
92. Sadanandam A., Lyssiotis C.A., Homicsko K., Collisson E.A., Gibb W.J., Wullschleger S., et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nature Medicine 2013, 19:619-625.
93. Lee M.J., Ye A.S., Gardino A.K., Heijink A.M., Sorger P.K., MacBeath G., et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012, 149:780-794.
94. Loscalzo J., Barabasi A.L. Systems biology and the future of medicine. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 2011, 3:619-627.
95. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Current Opinion in Cell Biology 2005, 17:548-558.
96. Bredel M., Bredel C., Juric D., Harsh G.R., Vogel H., Recht L.D., et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Research 2005, 65:8679-8689.
97. Resendis-Antonio O., Checa A., Encarnación S. Modeling core metabolism in cancer cells: surveying the topology underlying the Warburg effect. PLoS ONE 2010, 5:e12383.
98. Vazquez A., Markert E.K., Oltvai Z.N. Serine biosynthesis with one carbon catabolism and the glycine cleavage system represents a novel pathway for ATP generation. PLoS ONE 2011, 6:e25881.